Positive therapy outcome of lung squamous cell cancer: A case report

Liu,Ying; Yang,Jian; Sun,Xue-Jia; Lu,Sheng-Nan; Liu,Shi

doi:10.3892/etm.2022.11360

Positive therapy outcome of lung squamous cell cancer: A case report

Authors:
- Ying Liu
- Jian Yang
- Xue-Jia Sun
- Sheng-Nan Lu
- Shi Liu
View Affiliations

Affiliations: Department of Medical Oncology, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China, Department of General Surgery, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154000, P.R. China, Department of Radiology Imaging, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China, Department of Ultrasonic Imaging, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China, Central Laboratory, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China
Published online on: May 9, 2022 https://doi.org/10.3892/etm.2022.11360
Article Number: 433

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Abstract. Lung cancer is a rapidly progressing disease with a poor prognosis. Lung squamous cell cancer (LSCC) accounts for 20‑30% of lung cancer cases. Conventional chemotherapy and radiotherapy are the common options for LSCC. Nevertheless, the outcomes of these treatments are still unsatisfactory. The present report describes a rare case of LSCC with pericardial, cervical lymph node and extensive mediastinal lymph node metastases, who still survives today, in March 2022, more than 10 years after therapy and, therefore, this case study indicates a possible treatment regimen for patients with a similar condition. In conclusion, gemcitabine and cisplatin followed by radiotherapy were an effective treatment against pericardial and lymph node metastases from LSCC.

View Figures

View References

1	Tan PS, Bilger M, de Lima Lopes G, Acharyya S and Haaland B: Meta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populations. Cancer Med. 6:1847–1860. 2017.PubMed/NCBI View Article : Google Scholar
2	Osmani L, Askin F, Gabrielson E and Li QK: Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 52:103–109. 2018.PubMed/NCBI View Article : Google Scholar
3	Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018.PubMed/NCBI View Article : Google Scholar
4	Alexander M, Kim SY and Cheng HY: Update 2020: Management of non-small cell lung cancer. Lung. 198:897–907. 2020.PubMed/NCBI View Article : Google Scholar
5	Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, et al: Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE collaborative group. J Clin Oncol. 26:3552–3559. 2008.PubMed/NCBI View Article : Google Scholar
6	Lemjabbar-Alaoui H, Hassan OU, Yang YW and Buchanan P: Lung cancer: Biology and treatment options. Biochim Biophys Acta. 1856:189–210. 2015.PubMed/NCBI View Article : Google Scholar
7	Liu TT, He Z, Dang J and Li G: Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: A systematic review and network meta-analysis. Radiat Oncol. 14(55)2019.PubMed/NCBI View Article : Google Scholar
8	Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, et al: NCCN guidelines insights: Non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw. 16:807–821. 2018.PubMed/NCBI View Article : Google Scholar
9	Ma D, Wang J, Hao X, Wang Y, Hu X, Xing P and Li J: Gemcitabine combined with cisplatin as adjuvant chemotherapy for non-small cell lung cancer: A retrospective analysis. Thorac Cancer. 8:482–488. 2017.PubMed/NCBI View Article : Google Scholar
10	Yang CH, Tsai CM, Wang LS, Lee YC, Chang CJ, Lui LT, Yen SH, Hsu C, Cheng AL, Liu MY, et al: Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer. Br J Cancer. 86:190–195. 2002.PubMed/NCBI View Article : Google Scholar
11	Zwitter M, Kovac V, Smrdel U and Strojan P: Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer. J Thorac Oncol. 1:662–666. 2006.PubMed/NCBI
12	Das M, Donington JS, Murphy J, Kozak M, Eclov N, Whyte RI, Hoang CD, Zhou L, Le QT, Loo BW and Wakelee H: Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer. Clin Lung Cancer. 12:280–285. 2011.PubMed/NCBI View Article : Google Scholar
13	Driesen P, Lambrechts M, Kraaij K, Soldatenkova V, Chouaki N and Colinet B: A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer. Ther Adv Med Oncol. 5:159–168. 2013.PubMed/NCBI View Article : Google Scholar